Clinical Trial

TAS1553-01: A Phase 1 Study of Safety, Pharmacokinetics and Preliminary Activity of TAS1553 in Subjects with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms

This is a research study to test a new drug called TAS1553 that is not approved by the Food and Drug Administration (FDA) to treat relasped or refractory acute myeloid leukemia (AML) or another cancer of the bone marrow, for example, myeloid neoplasms. We are looking to test the safety of the study drug, how much of the study drug is in your body based on what dose you get, how the study drug works on your cancer, and to find the appropriate dose of this study drug to use in this and other future studies.

• Acute Myeloid Leukemia
• AML
• Cancer